| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4286509
Max Phase: Preclinical
Molecular Formula: C22H16BrN5O3S
Molecular Weight: 510.37
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: O=C(O)c1cccc(NC(=S)NNc2nc3ccccc3c(=O)n2-c2cccc(Br)c2)c1
Standard InChI: InChI=1S/C22H16BrN5O3S/c23-14-6-4-8-16(12-14)28-19(29)17-9-1-2-10-18(17)25-21(28)26-27-22(32)24-15-7-3-5-13(11-15)20(30)31/h1-12H,(H,25,26)(H,30,31)(H2,24,27,32)
Standard InChI Key: ZMSUTFXMLOOCLJ-UHFFFAOYSA-N
Associated Targets(Human)
MIA PaCa-2 5949 Activities
Associated Targets(non-human)
Cholecystokinin B receptor 729 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Cholecystokinin B receptor 792 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 510.37 | Molecular Weight (Monoisotopic): 509.0157 | AlogP: 4.16 | #Rotatable Bonds: 5 |
| Polar Surface Area: 108.28 | Molecular Species: ACID | HBA: 6 | HBD: 4 |
| #RO5 Violations: 1 | HBA (Lipinski): 8 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: 3.94 | CX Basic pKa: 2.38 | CX LogP: 4.94 | CX LogD: 1.88 |
| Aromatic Rings: 4 | Heavy Atoms: 32 | QED Weighted: 0.23 | Np Likeness Score: -1.64 |
References
| 1. Kumari S, Chowdhury J, Sikka M, Verma P, Jha P, Mishra AK, Saluja D, Chopra M.. (2017) Identification of potent cholecystokinin-B receptor antagonists: synthesis, molecular modeling and anti-cancer activity against pancreatic cancer cells., 8 (7): [PMID:30108868] [10.1039/C7MD00171A] |
Source
Source(1):